Evidence map›Paper›PMID 40874590›Full record

ArticleNucleic acids research2025

A DNA nicking Class 1 OLD family nuclease mediates phage defense in Vibrio cholerae and is countered by a phage-encoded inhibitor.

Kishen M Patel, Kimberley D Seed

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The uncharacterizedmicroPublication biology · 2026
    Article
  6. Specificity and mechanism of tRNA cleavage by the AriB Toprim nuclease of the PARIS bacterial immune system.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Kishen M PatelInfectious Diseases and Immunity Graduate Group, School of Public Health, University of California, Berkeley, Berkeley, CA, 94720, United States.
Kimberley D SeedDepartment of Plant and Microbial Biology, University of California, Berkeley, Berkeley, CA, 94720, United States.ORCID 0000-0002-0139-1600

Funding

Molecular mechanisms driving the coevolution of clinical isolates of phages and epidemic Vibrio choleraeR01AI153303 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Kimberley Diane Seed · 2020 to 2026
$4.3M
Burroughs WellcomeNational Institute of Allergy and Infectious Diseases R01AI153303NIAID NIH HHS R01 AI153303NIHPathogenesis of Infectious Disease AwardUC Dissertation-Year Fellowship
6 · The paper itself

Abstract

Bacteria are constantly threatened by their viral predators (phages), which has resulted in the development of defense systems for bacterial survival. One family of defense systems found widely across bacteria are OLD (for overcoming lysogenization defect) family nucleases. Despite recent discoveries regarding Class 2 and 4 OLD family nucleases and how phages overcome them, Class 1 OLD family nucleases remain underexplored, with only one antiphage Class 1 OLD family nuclease described to date. Here, we identify the first bacterially encoded Class 1 OLD family nuclease with antiphage activity: the Vibrio cholerae-encoded Vc OLD. We describe its disruption of genome replication of the lytic vibriophage ICP1. Furthermore, we examine its in vitro activity, identifying Vc OLD as a DNA nickase. Finally, we identify the first direct inhibitor of a Class 1 OLD family nuclease, the ICP1-encoded Oad1. Our research sheds new light on the role of Class 1 OLD family nucleases in phage defense and highlights the dynamic arms race between V. cholerae and its predatory phage ICP1.

Indexed as

Bacterial ProteinsBacteriophagesVibrio choleraeViral ProteinsBacterial ProteinsViral Proteins

Identifiers

PMID40874590
PMCPMC12392090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.